| Literature DB >> 31364808 |
Minna P Mustikka1, Thomas S C Grönthal1, Elina M Pietilä1.
Abstract
OBJECTIVE: To retrospectively describe laboratory findings, treatment, and outcome associated with equine infectious keratitis in Finland. ANIMALS AND PROCEDURES: Medical records of horses diagnosed with infectious keratitis in University of Helsinki Equine Hospital from January 2007 to June 2018 were reviewed.Entities:
Keywords: bacterial keratitis; cornea; equine; fungal keratitis; isolates; susceptibility
Mesh:
Substances:
Year: 2019 PMID: 31364808 PMCID: PMC7004187 DOI: 10.1111/vop.12701
Source DB: PubMed Journal: Vet Ophthalmol ISSN: 1463-5216 Impact factor: 1.644
Figure 1Seasonal distribution of equine cases diagnosed with fungal or bacterial keratitis in Finland from January 2007 to June 2018
Figure 2Annual distribution of equine cases diagnosed with fungal or bacterial keratitis in Finland form January 2007 to June 2018
Bacterial organisms isolated from equine cases of bacterial keratitis in Finland from January 2007 to June 2018
| Organism | No. of isolates |
|---|---|
|
| 9 |
|
| 4 |
|
| 2 |
| Coagulase‐negative staphylococci | 1 |
|
| 1 |
|
| 1 |
|
| 1 |
Antimicrobial susceptibility results of Streptococcus equi subsp. zooepidemicus isolates diagnosed in cases of equine bacterial keratitis in Finland from January 2007 to June 2018
| N | PCG | TMPS | ERY | CLI | TC | CHL | CIP | FUS | GEN | MOX |
| Resistant | 0 | 0 | 0 | 2 | 3 | 0 | 3 | 6 | 0 | 0 |
| Susceptible | 9 | 8 | 3 | 1 | 4 | 8 | 2 | 0 | 2 | 1 |
| Total | 9 | 8 | 3 | 3 | 7 | 8 | 5 | 6 | 2 | 1 |
| % Susceptible | 100.0 | 100.0 | 100.0 | 33.3 | 57.1 | 100.0 | 40.0 | 0.0 | 100.0 | 100.0 |
Abbreviations: CHL, chloramphenicol; CIP, ciprofloxacin; CLI, clindamycin; ERY, erythromycin; FUS, fusidic acid; GEN, gentamicin; MOX, moxifloxacin; PCG, penicillin G; TC, tetracycline; TMPS, trimethoprim sulfadiazine.
Fungal organisms isolated from cases of equine fungal keratitis in Finland from January 2007 to June 2018
| Organism | No. of isolates |
|---|---|
|
| 9 |
|
| 2 |
|
| 2 |
|
| 1 |
|
| 1 |
|
| 1 |
|
| 1 |
Minimal inhibitory concentrations in mg/L for Aspergillus flavus and Cylindrocarpon sp. isolates in cases of equine fungal keratitis in Finland from January 2007 to June 2018
| Amphotericin B | Itraconazole | Posaconazole | Voriconazole | |
|---|---|---|---|---|
|
| ||||
| 1 | 1 | 1 | 0.25 | 0.38 |
| 2 | 16 | 1.5 | 0.25 | 0.19 |
| 3 | 2 | 0.75 | 0.38 | 0.19 |
| 4 | 3 | 1 | 0.25 | 0.5 |
| 5 | 1.5 | 1.5 | 0.38 | 0.19 |
| 6 | 2 | 0.38 | 0.19 | 0.19 |
| 7 | 4 | 1.5 | 0.25 | 0.19 |
| 8 | 12 | 1 | 0.19 | 0.125 |
| 9 | 3 | 1 | 0.25 | 0.19 |
|
| ||||
| 1 | 8 | >32 | >32 | 4 |
| 2 | 2 | 32 | 32 | 3 |
| 3 | 24 | >32 | >32 | 8 |
Breakpoints in mg/L for interpretation of minimal inhibitory concentrations of Aspergillus fumigatus according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) Antifungal Clinical Breakpoint Table v. 9.028
| Sensitive | Resistant | |
|---|---|---|
| Amphotericin B | ≤1 | ≥2 |
| Itraconazole | ≤1 | >2 |
| Posaconazole | ≤0.125 | >0.25 |
| Voriconazole | ≤1 | >2 |
Medical therapy of 45 cases with infectious keratitis diagnosed in Finland from January 2007 to June 2018
| Medication | Route | Dose | No. of cases | % of cases |
|---|---|---|---|---|
| Antimicrobial | ||||
| Trimethoprim sulfadiazine | Oral | 30 mg/kg BID | 17 | 38 |
| Doxycycline | Oral | 10 mg/kg BID | 1 | 2 |
| Chloramphenicol 5 mg/mL | Topical | Q 2‐6 h | 40 | 89 |
| Ofloxacin 3 mg/mL | Topical | Q 2‐6 h | 27 | 60 |
| Tobramycin 3 mg/mL | Topical | Q 12 h | 3 | 7 |
| Neomycin‐Polymyxin B‐Gramicidin | Topical | Q 2‐6 h | 2 | 4 |
| Fusidic acid 10 mg/mL | Topical | Q 12 h | 2 | 4 |
| Moxifloxacin 5 mg/mL | Topical | Q 2‐6 h | 1 | 2 |
| Tetracycline 10 mg/mL | Topical | Q 8 h | 1 | 2 |
| Cefazolin | Subconjunctival | 100 mg | 1 | 2 |
| Antifungal | ||||
| Fluconazole | Oral | 14 mg/kg loading dose followed by 5 mg/kg SID | 7 | 16 |
| Voriconazole 10 mg/mL | Topical | Q 2‐6 h | 33 | 73 |
| Fluconazole 2 mg/mL | Topical | Q 2‐6 h | 13 | 29 |
| Amphotericin B 2.5‐5 mg/mL | Topical | Q 4‐6 h | 5 | 11 |
| Miconazole 2% | Topical | Q 8 h | 1 | 2 |
| Amphotericin B | Subconjunctival | 1 mg | 3 | 7 |
| Proteinase inhibition | ||||
| Serum | Topical | Q 2‐6 h | 26 | 58 |
| EDTA 2% | Topical | Q 2‐6 h | 4 | 9 |
| Mydriatics | ||||
| Atropine 1% | Topical | Q 6‐24 h | 45 | 100 |
| Phenylephrine 10% | Topical | Q 8 h | 1 | 2 |
Abbreviations: BID, twice a day; SID, once a day.